September 19, 2014 4:20 AM ET

Biotechnology

Company Overview of Biolex Therapeutics, Inc., LEX SystemSM and Two Biological Drug Candidates

Company Overview

AS of April 20, 2012, LEX SystemSM and Two Biological Drug Candidates of Biolex Therapeutics, Inc. were acquired by Synthon Holding B.V. LEX SystemSM and Two Biological Drug Candidates of Biolex Therapeutics, Inc. comprises LEX SystemSM, a proprietary biologics manufacturing platform and two promising biological drug candidates that produce proteins and antibodies.

,  

United States

Key Executives for Biolex Therapeutics, Inc., LEX SystemSM and Two Biological Drug Candidates

Biolex Therapeutics, Inc., LEX SystemSM and Two Biological Drug Candidates does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Biodesy, LLC United States
Ras Therapeutics, Inc. United States
Janus Biotherapeutics, Inc. United States
TARIS BioMedical, Inc. United States
Principia Biopharma Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Biolex Therapeutics, Inc., LEX SystemSM and Two Biological Drug Candidates, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.